MIRMMirum Pharmaceuticals, Inc.

$85.96+16% 1Y

Is the price fair?

What MIRM's price assumes

Mirum Pharmaceuticals, Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is measured against sales instead: 12.0× revenue.

12.0

Price / sales · no P/E: the last twelve months did not end in a profit

Details›
EV / EBIToperating margin −135%: the multiple describes the denominator
not meaningful
Market capitalisation
$7.15B

Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.

On our screens:Most shorted stocks